Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > Exp grows the best weed!!

<< Previous

Bullboard Posts

Next >>

Comment by Redearth7on Aug 04, 2020 2:30pm

96 Views

Post# 31362683

RE:Exp grows the best weed!!

Good post Motherlode5155 if you were one of the early investors in EXP then you must also be very disappointed in what you paid per share like so many others. I hope that any new options issued are also issued at .80 cents per share...fairs fair.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market